• HSCT is widely used to treat hematologic malignancies, and might be curative in some patients. (medscape.com)
  • Similar to the effect seen with hematologic malignancies, graft-vs-host disease (GVHD) is also associated with disease regression with solid tumors. (medscape.com)
  • The research we fund fits into four general categories: FA solid tumors, bone marrow failure and hematopoietic malignancies, FA genes and the FA DNA repair pathway, and body systems. (fanconi.org)
  • As tenured investigator in the NHLBI, Dr. Childs has focused his research on allogeneic stem cell transplantation and tumor immunology to treat aplastic anemia, hematological malignancies, and solid tumors. (nih.gov)
  • The majority of unrelated donor (UD) hematopoietic stem cell (HSC) transplants are performed across HLA-DP mismatches, which, if involving disparity in a host-versus-graft (HVG) direction for an alloreactive T cell epitope (TCE), have been shown by our group to be associated with poor clinical outcome in 2 cohorts of patients transplanted for hematopoietic malignancies and beta-thalassemia, respectively. (bvsalud.org)
  • My research interests have focused on tumor immunology and allogeneic immunotherapy for solid tumors and hematologic malignancies. (nih.gov)
  • In today's era, bone marrow transplantation has become standard care for hematologic malignancies and congenital or acquired disorders of the hematopoietic system. (zenonco.io)
  • Hematopoietic stem cell transplantation (HSCT) with high-dose chemo-radiotherapy is frequently used in the treatment of patients with hematologic malignancies. (bmrat.org)
  • CAR T therapy has revolutionized the treatment of several hematologic malignancies, but its application to solid tumors has been an ongoing industry challenge," said Zachary Roberts, M.D., Ph.D., Executive Vice President of Research & Development. (livermore.com)
  • The protective effect of seasonal influenza vaccination is reduced in patients with hematologic malignancy and recipients of an allogeneic hematopoietic stem cell transplant (HSCT) ( 5 , 6 ). (cdc.gov)
  • In the state of Victoria, after the initial 3 months of community transmission of pandemic (H1N1) 2009 virus, 50% of patients who died had an underlying hematologic malignancy ( 15 ). (cdc.gov)
  • It helps increase the bone marrow function that depends upon the treatment of the disease in eliminating the tumor cells with malignancy or generating the functional cells that replace the dysfunctional cells in certain disorders such as immune deficiency syndromes, hemoglobinopathies, and other diseases. (zenonco.io)
  • We conducted a meta-analysis study that evaluates the efficacy of palifermin on OM after HSCT in hematologic malignancy patients. (bmrat.org)
  • MM is the second most common hematologic malignancy with an incidence ranging from 4 to 6 per 100,000/year in the USA [ 3 - 5 ]. (oncotarget.com)
  • This includes circulating tumor-derived cell-free DNA ( cfDNA ) and tumor-derived circulating tumor cells ( CTCs ). (technologynetworks.com)
  • From the abstract: 'Liquid biopsy analytes such as circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) have been the most clinically studied assays and were initially limited to advanced-stage disease. (cdc.gov)
  • At the time we published this paper, we assumed that the mechanism of action was probably similar to that observed in patients with hematologic cancers," Dr. Childs said in an interview. (medscape.com)
  • 11. Alterations in NKG2A and NKG2C Subsets of Natural Killer Cells Following Epstein-Barr Virus Reactivation in CTLA4Ig-based Haploidentical Transplantation Is Associated With Increased Chronic Graft-Versus-Host Disease. (nih.gov)
  • We thought we would see a graft-vs-tumor effect, similar to the graft-vs-leukemia effect that occurs in hematologic cancers after transplantation. (medscape.com)
  • HSCT is able to induce a strong graft-vs-leukemia effect in patients with hematologic cancers and effectively put the disease in remission. (medscape.com)
  • The cancers that develop in FA individuals often occur at a much earlier age than what is observed in the general population and are difficult to treat due to the toxic effects of chemotherapy and radiation observed in this population. (fanconi.org)
  • FARF supports grants that focus on defining the pathogenesis of FA solid tumors and that seek novel strategies for early detection, prevention, and treatment of these cancers. (fanconi.org)
  • Although liquid biopsies have been extensively leveraged in cancer biology to detect cfDNA, including FDA-cleared tests for breast, ovarian, prostrate and non-small cell lung cancers, research continues to expand the repertoire of amenable tumors and technology. (technologynetworks.com)
  • To describe the genomic changes that occur in advanced pediatric cancers between the time of initial diagnosis and relapse, in cases for which paired tumor specimens are available. (ucbraid.org)
  • To explore approaches to diagnosing and profiling genomics of advanced pediatric cancers through evaluation of circulating tumor deoxyribonucleic acid (DNA). (ucbraid.org)
  • Our investigators and physicians realize that many challenges remain in the treatment of childhood cancers and genetic tumor predisposition syndromes but we are committed to improving outcomes for children and young adults with these diseases through cutting-edge basic and clinical research. (cancer.gov)
  • Therefore, starting SHRINK today is another important milestone for us and for patients worldwide, evaluating the synergetic effect of the concurrent administration of our lead candidate CYAD-01 with standard chemotherapy as first-line metastatic treatment for colorectal cancers. (life-sciences-europe.com)
  • However, additional physiological and biological barriers imposed by the hostile tumor microenvironment has limited the ability to target solid tumors. (borgernewsherald.com)
  • We are particularly excited to now turn our attention to developing Loqtorzi across multiple tumor types in combination with I-O agents that target the tumor microenvironment, such as our IL27-targeted antibody, casdozokitug, and our CCR8 inhibitor CHS-114, potentially greatly expanding the number of cancer patients achieving improved survival benefit. (platohealth.ai)
  • Research conducted during my hematology fellowship showed that metastatic solid tumors could be killed by allogeneic T cells. (nih.gov)
  • given as a tandemly administered pair of doses to subjects with one or more solid tumor(s) in the bone or metastatic solid tumors to the bone that are visible on bone scan. (rwjbh.org)
  • To determine the frequency and spectrum of germline cancer susceptibility mutations in children with relapsed solid tumors and non-Hodgkin lymphomas and assess the feasibility of return of those results in the National Clinical Trial Network (NCTN) group setting. (ucbraid.org)
  • However, Dr. Childs points out that as they continued to observe the patients who had undergone HSCT, a number of them were experiencing tumor regression without any evidence of GVHD. (medscape.com)
  • My clinical research program has focused on expanding the application of nonmyeloablative allogeneic hematopoietic stem-cell transplantation to treat solid tumors and nonmalignant hematological disorders such as paroxysmal nocturnal hemoglobinuria (PNH). (nih.gov)
  • Subsequently, CSCs were identified in various solid and hematological tumors, including MM [ 11 - 15 ]. (oncotarget.com)
  • KEYTRUDA monotherapy remains a standard of care for the first-line treatment of certain patients with metastatic non-small cell lung cancer whose tumors express PD-L1. (merck.com)
  • To obtain preliminary information on the response rate to targeted therapy in patients whose tumors lack actionable alterations as defined for the molecular analysis for therapy choice (MATCH) study, for selected agents for which efficacy is observed in the primary matched cohort. (ucbraid.org)
  • In the 10 patients whose tumors were known to express CD70, the disease control rate was 100%, which included three patients who achieved partial remission (two confirmed, one unconfirmed). (livermore.com)
  • Brainstem gliomas, medulloblastomas, ependymomas, and certain pineal tumors are relatively common primary malignant tumors of the CNS in children. (nih.gov)
  • February 22, 2008 - Allogeneic hematopoietic stem cell transplantation (HSCT) has been shown to cause tumor regression in some patients with metastatic renal cell carcinoma, and there is evidence suggesting that disease regression is mediated by donor T cells that target antigens expressed on the tumor cells. (medscape.com)
  • 4. Early and Sustained Expansion of Adaptive Natural Killer Cells Following Haploidentical Transplantation and CTLA4Ig-Primed Donor Lymphocyte Infusions Dissociate Graft-versus-Leukemia and Graft-versus-Host Effects. (nih.gov)
  • 5. Prophylactic Donor Lymphocyte Infusion (DLI) Followed by Minimal Residual Disease and Graft-versus-Host Disease-Guided Multiple DLIs Could Improve Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Refractory/Relapsed Acute Leukemia. (nih.gov)
  • 8. Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease? (nih.gov)
  • hematopoietic stem cell transplantation (HSCT) is the only curative therapy for the hematologic manifestations of FA, but the high risk for solid tumors remains and may even be increased in those undergoing HSCT. (nih.gov)
  • It is categorized into two significant subtypes: autologous, where a patient donates the marrow stem cells to themselves, and allogeneic, which is a complex process of bone marrow transplantation where a patient receives the stem cell graft from a healthy donor. (zenonco.io)
  • Oral mucositis (OM) is one of the most common side effects after hematopoietic stem cell transplantation (HSCT) and palifermin is used for prophylactic use to prevent OM. (bmrat.org)
  • IL‐12/18 preactivated NK cells mediated stronger GVL (Graft vs. Lymphoma) effect than control NK cells mainly due to their elevated activation/cytotoxicity and sustained proliferative potential. (jeffreydachmd.com)
  • This phase I trial studies the side effects and best dose of pevonedistat when given together with irinotecan hydrochloride and temozolomide in treating patients with solid tumors , central nervous system (CNS) tumors, or lymphoma that have come back after a period of improvement (recurrent) or that do not respond to treatment (refractory). (ucsf.edu)
  • Giving pevonedistat, irinotecan hydrochloride, and temozolomide may work better in treating patients with solid tumors, central nervous system (CNS) tumors, or lymphoma compared to irinotecan and temozolomide alone. (ucsf.edu)
  • Other indications for allogeneic HSCT include lymphoma, myeloma, and hematologic disorders like aplastic anaemia and thalassemia. (zenonco.io)
  • In patients with tumor fever, diseases commonly detected by 18 F-FDG PET include Hodgkin's disease and aggressive non-Hodgkin's lymphoma but also colorectal cancer and sarcoma. (snmjournals.org)
  • Researchers have now identified, using allogeneic T cells from a patient undergoing HSCT, what they believe to be the first solid tumor antigen. (medscape.com)
  • However, few data are available on the effect of HSCT on solid tumors and whether such tumors have susceptibility similar to allogeneic immunotherapy. (medscape.com)
  • However, it is somewhat unique among solid tumors because of its immunogenic properties, and is one of the few solid tumors to respond to HSCT. (medscape.com)
  • Twenty-nine patients experienced disease regression that was consistent with a graft-vs-tumor effect, which occurred at a median of 133 days after HSCT. (medscape.com)
  • conditioning regimen without radiation prior to HSCT to reduce the subsequent risk of developing solid tumors. (nih.gov)
  • Herein the authors review transplant considerations, transplant goals, conditioning regimens, donor choice, and graft manipulation strategies for patients with non-malignant disorders undergoing HSCT. (stanford.edu)
  • Other indications for autologous HSCT include autoimmune diseases such as multiple sclerosis, systemic sclerosis, and Crohn's disease and solid tumors such as sarcoma, germinal tumors, and neuroblastoma. (zenonco.io)
  • The meta-analysis showed that palifermin was associated with reductions in the incidence and severity of OM and also was effective and safe on OM after allo- or auto-HSCT, but did not seem to effect on the incidence and severity of aGVHD. (bmrat.org)
  • Of the 27 patients evaluated for final results -15 showed anti-tumor activity, 10 showed stable disease progression for 6-10 weeks, and 1 patient exhibited a partial remission (PR) on the 300 mg/m2 for 21 days. (wikipedia.org)
  • In this trial, ALLO-316 showed early anti-tumor activity with deepening responses over time. (livermore.com)
  • Anti-tumor activity was primarily observed in patients with tumors confirmed to express CD70. (livermore.com)
  • Dramatic progress in technology has improved our understanding of the basic biology of tumor immunology, and immune-based therapies represent one approach that could be integrated into current multimodal regimens to eradicate micrometastatic disease. (medscape.com)
  • C3161 Leukemia C132009 C6205 Childhood Central Nervous System Germ Cell Tumor Childhood Central Nervous System Germ Cell Tumor A germ cell tumor of the central nervous system occurring in children. (nih.gov)
  • A germ cell tumor that arises from the central nervous system during childhood. (nih.gov)
  • C5132 Childhood Central Nervous System Neoplasm C7928 Childhood Germ Cell Tumor C132009 C5969 Childhood Brain Stem Neoplasm Childhood Brain Stem Tumor Childhood Brain Stem Neoplasm A neoplasm that affects the brain stem and occurs during childhood. (nih.gov)
  • Merchant and colleagues also suggest that T-cell-depleting cancer therapies may eliminate beneficial immune responses and that immune reconstitution of patients with lymphopenic cancer could prevent metastatic recurrence of solid tumors. (medscape.com)
  • Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer at High Risk of Recurrence in Patients with Tumor Cell PD-L1 Expre. (wapakdailynews.com)
  • Cancer stem cells (CSCs) are believed to be the major cause of tumor recurrence [ 8 , 9 ]. (oncotarget.com)
  • Over the past decade, Andrew K. Godwin , professor and division director of Genomics Diagnostics, Department of Pathology and Laboratory Medicine, The University of Kansas (KU) Medical Center and deputy director, KU Cancer Center, has been developing liquid biopsy platforms to analyze the various materials shed by tumors to improve patient care. (technologynetworks.com)
  • STEP 1 (SCREENING): Patients undergo biopsy along with tumor mutational screening of the biopsy material for specific, pre-defined mutations, amplifications, or translocations of interest via tumor sequencing and immunohistochemistry. (ucbraid.org)
  • Immunotherapy with monoclonal antibodies, such as obinutuzumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. (policylab.us)
  • Part II: Identification and management of cutaneous side effects of immunotherapy treatments. (stanfordchildrens.org)
  • Tumor regression occurred in 6 patients who showed no evidence of acute GVHD, suggesting that antigens that are overexpressed or even limited to the tumor are targets for immune cells that mediate disease regression. (medscape.com)
  • Do you or a child in your family have a cancerous tumor or blood disease? (nih.gov)
  • 100 days posttransplantation or severe graft-versus-host disease were admitted to an intensive care unit. (cdc.gov)
  • Disease status: Patients with refractory solid tumors including patients with NF1 and MPNST must have evaluable disease, patients with leukemia must have measurable or evaluable disease at the time of enrollment, which may include any evidence of disease including minimal residual disease detected by flow cytometry. (nih.gov)
  • The IL‐12/18 preactivated NK cells mitigate aGVHD (Acute Graft vs. Host) despite the severity of the disease. (jeffreydachmd.com)
  • Some involve leukaemias, bone marrow failures, hemoglobinopathies (thalassemia, sickle cell disease), immunodeficiencies, and other HSC transplant-based treatments for solid tumors and other genetic disorders such as lysosomal storage disease along with autoimmunity. (zenonco.io)
  • p = 0.01], but there were no significant differences in acute graft versus host disease (aGVHD) grades, infection and blood stream infection between two groups. (bmrat.org)
  • Period after successful treatment in which there is no appearance of the symptoms or effects of the disease. (lookformedical.com)
  • Donor-derived T-cells are transduced using a lentiviral vector to express the anti-CD123 chimeric antigen receptor (CAR) and are further modified using Cellectis' TALEN® technology to disrupt the T-cell receptor alpha constant (TRAC) and CD52 genes to minimize risk of graft-vs-host disease (GvHD) and allow use of anti-CD52-directed therapy as a component of the LD regimen, respectively. (borgernewsherald.com)
  • Due to the location of the primary tumor, surgery is rarely an option, and patients with localized disease are treated primarily with radiation and chemotherapy. (platohealth.ai)
  • Biomarker analyses from CheckMate -274 evaluating adjuvant Opdivo in patients with muscle-invasive urothelial carcinoma, including tumor and immune features associated with disease-free survival. (bms.com)
  • És un expert en neuroblastoma i desenvolupament de fàrmacs a Europa i treballa per a xarxes internacionals com SIOPEN (siopen.net) i ITCC (itcc-consortium.org). (vallhebron.com)
  • Dirigeix l'assaig clinic BEACON-Neuroblastoma obert en 10 països europeus per neuroblastoma en recaiguda o refractari. (vallhebron.com)
  • Various murine studies have reported that both spontaneous and carcinogen-induced tumors occur more frequently in mice that lack various elements of innate and adaptive immunity. (medscape.com)
  • The challenge to the current field is to elucidate the biology of host-tumor interactions at the time of clinical presentation with cancer and to develop approaches that diminish the capacity for tumors to evade immunity and amplify host antitumor immune responses. (medscape.com)
  • Adaptive immunity induces immunologic memory and can directly kill tumor cells or recruit other effectors through cytokine production. (medscape.com)
  • It entirely depends upon the effect of the graft and donor immunity against malignant cells in recipients. (zenonco.io)
  • This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors , non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists that has been shown to prolong survival. (ucbraid.org)
  • To utilize clinical and biological data to screen for eligibility to phase 2 pathway-targeting specific subprotocols of pathway-targeting agents in pediatric patients with advanced solid tumors, non-Hodgkin lymphomas, and histiocytic disorders . (ucbraid.org)
  • complete response + partial response) in pediatric patients with advanced solid tumors, non-Hodgkin lymphomas, and histiocytic disorders harboring a priori specified genomic alterations treated with pathway-targeting agents. (ucbraid.org)
  • To estimate the progression free survival in pediatric patients receiving targeted therapies for advanced solid tumors, non-Hodgkin lymphomas, and histiocytic disorders. (ucbraid.org)
  • To increase knowledge of the genomic landscape of advanced pediatric solid tumors , non-Hodgkin lymphomas, and histiocytic disorders. (ucbraid.org)
  • Transplant for non-malignant disorders: an International Society for Cell & Gene Therapy Stem Cell Engineering Committee report on the role of alternative donors, stem cell sources and graft engineering. (stanford.edu)
  • Patients must have recurrent or refractory solid tumors or acute leukemia (limited to AML or ALL) or have been intolerant of prior therapies, confirmed by the Laboratory of Pathology, NCI, e.g., solid tumors including rhabdomyosarcoma, Ewing sarcoma, soft tissue sarcomas. (nih.gov)
  • Childhood Neurogenic Sarcoma A malignant peripheral nerve sheath tumor occurring in children. (nih.gov)
  • 153Sm-DOTMP) to Treat Solid Tumor(s) in the Bone or Metastatic to the Bone (Metastatic Prostate, Breast, and Lung, Osteosarcoma, Ewings Sarcoma, and other solid tumor(s) to the bone all eligible). (rwjbh.org)
  • We found that the antigen was restricted to the tumor," said lead author Richard Childs, MD, from the National Heart, Lung, and Blood Institute's Hematology Branch. (medscape.com)
  • Dr. Childs and his research team were the first to establish the existence of a graft-vs-solid tumor effect mediated by transplanted donor T-cells that could cure patients with metastatic renal cell carcinoma. (nih.gov)
  • In this regard, his group has cloned T-cell receptors recognizing HERV-E antigens and in a first in human clinical trial being conducted at the NIH Clinical Center, is investigating the anti-tumor potential of adoptively transferring autologous T-cells genetically modified to express HERV-E T-cell receptors. (nih.gov)
  • In KEYNOTE-598, the addition of ipilimumab to KEYTRUDA did not improve overall survival or progression-free survival, and patients who received the combination were more likely to experience serious side effects than those who received KEYTRUDA monotherapy," said Dr. Michael Boyer, chief clinical officer and conjoint chair of thoracic oncology, Chris O'Brien Lifehouse, Camperdown, NSW, Australia. (merck.com)
  • The use of ctDNA-based molecular genotyping for tumor profiling and identification of patients eligible for targeted therapies has been integrated into clinical practice for a variety of tumor types. (cdc.gov)
  • 2. To assess the clinical response of solid tumors to the bone or metastatic to the bone to therapy with infusional CylcoSam? (rwjbh.org)
  • WHO) Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia (AML), and it is treated differently than other types of AML because of its marked sensitivity to differentiating effects of all trans-retinoic acid. (nih.gov)
  • citation needed] Due to negative results of the stand-alone Phase I trial, and knowledge that NAMI-A slows down progression of metastasis, and not growth of the initial tumor, Phase I & II trials were done using gemcitabine, a nucleoside analog that has shown to be successful in treating lung cancer. (wikipedia.org)
  • Opdivo- based treatments have shown improved efficacy in the neoadjuvant or adjuvant treatment of four tumor types: lung cancer, bladder cancer, esophageal/gastroesophageal junction cancer and melanoma. (wapakdailynews.com)
  • in addition to metastatic prostate cancer, this combination is also being studied in advanced lung cancer, ovarian cancer, and triple-negative breast cancer, as well as across solid tumors with certain biomarkers. (merck.com)
  • Tumors or cancer of the LUNG. (lookformedical.com)
  • We only found it in kidney cancer cells, not in any of the other tumors that we looked at. (medscape.com)
  • It can directly kill tumor cells. (medscape.com)
  • T cells are potent tumor cell killers that recognize peptides derived from the target cell (extracellular or intracellular) but must be presented by major histocompatibility complex (MHC) molecules. (medscape.com)
  • One trial was done to test the efficacy of NAMI-A in female grafted with MCa mammary carcinoma cells. (wikipedia.org)
  • Dr Senju in 2018 studied the effect of IL12 and IL18 on expansion of Human Natural Killer Cells (NK Cells). (jeffreydachmd.com)
  • Genetic tests look at the unique genetic material (genes) of patients' tumor cells. (ucbraid.org)
  • A cell line derived from cultured tumor cells. (lookformedical.com)
  • Multiple myeloma (MM) is a hematologic cancer characterized by proliferation of clonal plasma cells in the bone marrow (BM) resulting in the secretion of monoclonal immunoglobulins [ 1 , 2 ]. (oncotarget.com)
  • From the article: 'Cell-free circulating tumor DNA (ctDNA) is shed by tumor cells into the systemic circulation and, thanks to advancements in next-generation sequencing (NGS) technologies, affords the opportunity to noninvasively detect cancer-specific somatic variants. (cdc.gov)
  • This glimpse of success also demonstrated that we need to be able to creatively customize and equip CAR T-cells to target these tumors. (borgernewsherald.com)
  • This study aimed to evaluate the effect of cryopreservation on breast cancer cells. (researchsquare.com)
  • However, data about effect of cryopreservation procedure on viability of cancer cells are limited. (researchsquare.com)
  • This study aimed to evaluate the effect of cryopreservation on ZR-75-1 and MDA-MB-231 human breast cancer cells in the form of compacted fragments (as a model of solid tumors). (researchsquare.com)
  • Adequate hematologic function, defined as a platelet count >100,000 cells/mm3 and an absolute neutrophil count (ANC) >1,000 cells/mm3. (rwjbh.org)
  • In addition, patients with NF1 and with malignant peripheral nerve sheath tumor (MPNST). (nih.gov)
  • This led them to hypothesize that the immune response occurred against antigens that are overexpressed or even selectively expressed on the tumor site. (medscape.com)
  • Evidence currently suggests that the mechanisms responsible for resistance to cytotoxic agents generally do not confer resistance to immune-mediated mechanisms of tumor-cell killing. (medscape.com)
  • Patients develop spontaneous innate and acquired immune responses to their tumors. (medscape.com)
  • In summary, current models hold that tumor antigens are present and induce immune reactivity during incipient tumor growth and that tumors subsequently develop properties to evade these immune responses. (medscape.com)
  • 1) A large volume of medical research through the 1980's and 90's investigated the various anti-cancer mechanisms of Cimetidine seeming to involve the drug's ability to reverse immune tumor evasion, block immunosuppressive effects of histamine, and stimulate host immune cell expansion. (jeffreydachmd.com)
  • Loqtorzi is a next-generation, programmed death receptor-1 (PD-1) monoclonal antibody that blocks PD-1 ligands PD-L1 and PD-L2 with high potency at a unique site on the PD-1 receptor, enabling the immune system to activate and kill the tumor. (platohealth.ai)
  • Immunosuppressed transplant recipients display higher incidences of nonviral tumors than age-matched immunocompetent controls. (medscape.com)
  • Participants in this study must be 2 years or older and either have a cancerous tumor or a cancerous or non-cancerous blood disorder, or be a compatible family member for a stem cell transplant for the patient. (nih.gov)
  • The purpose of this study is to see if giving reduced intensity chemotherapy, haploidentical bone marrow, post-transplant cyclophosphamide and shortened duration tacrolimus is safe and feasible for patients with very high-risk solid tumors. (centerwatch.com)
  • It is mainly integrated as a therapeutic option in case of the occurrence of solid tumors. (zenonco.io)
  • Solid tumors - particularly of the head and neck, skin, and genitourinary tract - are more common in individuals with FA. (nih.gov)
  • This phase II trial studies how well reduced doses of radiation therapy to the brain and spine (craniospinal) and chemotherapy work in treating patients with newly diagnosed type of brain tumor called WNT)/Wingless (WNT)-driven medulloblastoma. (centerwatch.com)
  • cfDNA can harbor mutations present in the tumor. (technologynetworks.com)
  • Patients with genetic changes or abnormalities (mutations) may benefit more from treatment which targets their tumor's particular genetic mutation , and may help doctors plan better treatment for patients with solid tumors or non-Hodgkin lymphomas. (ucbraid.org)
  • Concurrent Tissue and Circulating Tumor DNA Molecular Profiling to Detect Guideline-Based Targeted Mutations in a Multicancer Cohort. (cdc.gov)
  • Subsequently, his laboratory discovered a novel human endogenous retrovirus (HERV-E) to be the target for allogeneic graft-vs-tumor effects inducing tumor regression. (nih.gov)
  • The Pediatric Oncology Branch is dedicated to improving outcomes for children and young adults with cancer and genetic tumor predisposition syndromes. (cancer.gov)
  • 2. Subjects must have a histologically confirmed diagnosis of a solid tumor metastatic to bone, or a histologically confirmed diagnosis of a solid tumor to the bone or metastatic to the bone. (rwjbh.org)
  • Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies. (nih.gov)
  • To determine the proportion of pediatric patients whose advanced tumors have pathway alterations that can be targeted by select anti-cancer drugs. (ucbraid.org)
  • With the development of new preparative regimens, expanded alternative donor availability, and graft manipulation techniques, there are many options when choosing the best regimen for patients. (stanford.edu)
  • The treatment continues to be well tolerated in the larger patient population, with minimal side effects beyond the expected myelosuppression from the preceding lymphodepleting chemotherapy. (affimed.com)
  • Responsiveness is defined as a tumor demonstrating either a complete or partial remission. (aetna.com)
  • Several side effects were observed including: Mild hematologic toxicity - blood related toxicity Nausea Vomiting Diarrhea Stomatitis - inflammation of mouth and lips Fatigue Creatinine increase - common toxicity (CTC) grade 1 and 2 - High levels indicate kidney dysfunction Fever Sensitivity reactions to drug Phlebitis at injection site Blisters on hands and feet Of the 24 patients in the study, 20 were evaluated for final results. (wikipedia.org)
  • The highest dose of a biologically active agent given during a chronic study that will not reduce longevity from effects other than carcinogenicity. (lookformedical.com)
  • Today s announcement, in conjunction with our ongoing THINK trial and the upcoming LINK study, reaffirms our commitment and dedication to beat cancer with a strong focus on solid tumors. (life-sciences-europe.com)
  • 7. Subjects must have adequately recovered from the effects of any prior chemotherapy, as determined by the treating physician and study team, based in part on organ function defined above. (rwjbh.org)
  • When used at high doses in dose-ranging studies in patients with acute leukemia, fludarabine phosphate for injection was associated with severe neurologic effects, including blindness, coma, and death. (nih.gov)
  • In the context of cancer, for instance, this consists of detecting biomolecules shed by the growing solid tumor into circulation, i.e., blood. (technologynetworks.com)
  • Some people with cancer have solid tumors. (nih.gov)
  • To find the highest safe dose and side effects of Turalio(R). To see if it helps treat certain types of cancer. (nih.gov)
  • People ages 3-35 with a solid tumor or leukemia that has returned or not responded to cancer therapies. (nih.gov)
  • Patients must have fully recovered (to Grade 1) from the acute toxic effects of all prior anti-cancer therapy. (nih.gov)
  • Tumors or cancer of the OVARY. (lookformedical.com)
  • Tumors or cancer of the human BREAST. (lookformedical.com)
  • A neoplasm that affects the brain stem and occurs during childhood. (nih.gov)